Analyst Price Targets — ACOG
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 17, 2026 3:24 pm | Raghuram Selvaraju | H.C. Wainwright | $20.00 | $8.80 | TheFly | Alpha Cognition price target raised to $20 from $18 at H.C. Wainwright |
| August 14, 2026 1:29 pm | — | Craig-Hallum | $17.00 | $8.94 | TheFly | Alpha Cognition price target raised to $17 from $14 at Craig-Hallum |
| July 10, 2026 10:12 am | Ryan Deschner | Raymond James | $20.00 | $8.52 | TheFly | Alpha Cognition initiated with an Outperform at Raymond James |
| May 29, 2026 11:46 am | — | Maxim Group | $12.00 | $5.85 | TheFly | Alpha Cognition initiated with a Buy at Maxim |
| April 17, 2026 11:31 am | — | Craig-Hallum | $14.00 | $6.65 | TheFly | Alpha Cognition initiated with a Buy at Craig-Hallum |
| October 20, 2025 12:20 pm | — | H.C. Wainwright | $18.00 | $6.80 | TheFly | Alpha Cognition price target lowered to $18 from $20 at H.C. Wainwright |
Latest News for ACOG
VANCOUVER, British Columbia & GRAPEVINE, Texas--(BUSINESS WIRE)--Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that on August 31st, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards…
Dallas, Texas--(Newsfile Corp. - August 17, 2026) - Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition's 2Q26 strengthens the ZUNVEYL launch setup, with results ahead of prior expectations and demand accelerating despite slower payer implementation.
Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.65 per share a year ago.
Alpha Cognition NASDAQ: ACOG reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer's treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter, as the company cited growing prescriber adoption and deeper use in long-term care facilities.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ACOG.
U.S. House Trading
No House trades found for ACOG.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.